KATIE WOHLGEMUTH: Open Payments
NPI 1548920820 · TOPEKA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,020 in 45 payments from 14 companies in 2025. Trend: 2023 $75 · 2024 $788 · 2025 $1,020
Food & beverage: $931Education: $89
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $266 |
| Amgen Inc. | 8 | $150 |
| Novartis Pharmaceuticals Corporation | 7 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $89 |
| GlaxoSmithKline, LLC. | 4 | $79 |
| Genentech USA, Inc. | 2 | $60 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $48 |
| BioCryst US Sales Co., LLC | 2 | $38 |
| Integra LifeSciences Corporation | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $33 |
Products named: TEZSPIRE, FASENRA, DUPIXENT, Xolair, Rhapsido, NUCALA, ORLADEYO, ACCLARENT AERA.
Industry payments across KS — which companies pay providers there.
